Kexing Biopharm (688136.SH) plans to launch a restricted stock incentive plan in 2026.

20:00 15/06/2026

Covax Pharma (688136.SH) disclosed the restricted stock incentive plan (draft) for the year 2026, with the plan intending to grant 4.943 million shares of restricted stock to the incentive recipients, accounting for 2.46% of the total share capital of the company as of the announcement date of the draft incentive plan. The grant price for the restricted stock is 14.35 yuan per share.

Kexing Biopharm (688136.SH) disclosed its 2026 Restricted Stock Incentive Plan (Draft), which proposes to award a total of 4.943 million restricted stocks to incentive recipients, accounting for 2.46% of the total share capital of the company as of the announcement date of the incentive plan draft. The grant price for the restricted stocks is set at 14.35 yuan per share. This incentive plan aims to award a total of 197 incentive recipients, representing 18.8% of the total number of company employees (as of December 31, 2025, the total number of company employees was 1048), including company directors, senior executives, core technical (business) personnel, and other individuals considered deserving of incentive by the board of directors.

HK Stock Market Move | AAC TECH (02018) rises by over 5% again. SRG optical waveguide lenses pass head customer testing and mass production.

BOCOM INTL: AXERA (00600) is given a "buy" rating with a target price of HK$36.

HK Stock Market Move | Jl Mag Rare-Earth (06680) rose nearly 7% as Japanese and Korean MLCC leading companies fully expanded production, leading to a surge in demand for high-purity dysprosium oxide driven by the outbreak of AI high-capacity MLCC.

HK Stock Market Move | AAC TECH (02018) rises by over 5% again. SRG optical waveguide lenses pass head customer testing and mass production.

BOCOM INTL: AXERA (00600) is given a "buy" rating with a target price of HK$36.